- Izotropic Corporation (IZO) has released a video showcasing the completed engineering of IzoView
- Izotropic has designed and built the first commercial breast CT imaging system
- Izotropic Corporation is commercializing a dedicated breast CT imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers
- Izotropic Corp. (IZO) is down 2.70 per cent on the day, trading at C$0.72 per share at 1:30 pm ET
Izotropic Corporation (IZO) has released a video showcasing the completed engineering of IzoView.
This video is the first in a series of presentations, interviews, and demonstrations of IzoView and its capabilities.
The video features Chief Operating Officer Dr. Younes Achkire and Head of Imaging Technology Dr. Andrew Hernandez.
“I am thrilled and proud of our team for achieving this critical milestone. It is a very exciting time for Izotropic!” – Dr. Younes Achkire, COO.
The team will be converging in Sacramento at the Company’s engineering facility from the 15th to the 23rd of January to outfit the facility in preparation for clinical and investment-related presentations and to complete a second phase of interviews with key scientific and clinical team members, including Dr. John Boone, Dr. Shadi Shakeri, Dr. Craig Abbey, Dr. Younes Achkire and Dr. Andrew Hernandez.
Dr. John M. Boone, Co-Founder & Director of Izotropic & Founder of IzoView Breast CT Technology, commented on the development of IzoView.
“I am a radiology professor and have lectured my students every year on how computed tomography is better than radiography for detecting subtle findings – textbook dogma. One day in the late 1990s, I sat down with a physicist friend and asked, “How can we really improve the detection and diagnosis of breast cancer?” Before he answered, I smiled, snapped my fingers, and said, “breast CT! Over a quarter century after that revelation – having built and tested four prototype breast CT scanners in my lab with the help of students, staff, post-docs, other medical physicists, radiologists, clinical coordinators, technologists, patients, and lots of research funding, the amazing team of engineers at Izotropic has designed and built the first commercial breast CT scanner that stems from the research experience gained in my laboratory at UC Davis. In my long academic career, breast CT represents my life’s most important scientific achievement, especially in terms of its impact on women’s lives. When our clinical trials started, I looked at the breast CT images with my colleague radiologists, and they would tell me how these 3D images would better inform their diagnostic capabilities. It was their enthusiasm and my nerdy passion for CT technology that kept me going on this long endeavour to better understand the physics of breast CT, its role in clinical practice, and how to optimize the breast CT machine to maximize its impact in that role.”
Izotropic Corporation is commercializing a dedicated breast CT imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers. In follow-on clinical studies, Izotropic intends to validate platform applications, including breast screening in radiology, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstructive surgery.
Izotropic Corp. (IZO) is down 2.70 per cent on the day, trading at C$0.72 per share at 1:30 pm ET.